Finally, to test whether ISB 2001 has any on-target off-tumor activity in vivo, we quantified the number of hematopoietic progenitors, B cell-committed progenitors and mature T cells present in the bone marrow of CD34+ humanized NXG mice 3 days after treatment with ISB 2001 (1.5 mg kg−1). This evidence concerns the gene CD34 and neoplasm.